Analyst firms · Oppenheimer · VRTX
Oppenheimer VRTX price target and rating history
Vertex Pharmaceuticals Incorporated (VRTX) · Health Care
Oppenheimer rates Vertex Pharmaceuticals Incorporated (VRTX) Outperform with a $600 price target, as of its latest action on Mar 10, 2026. It has published 3 rating actions on VRTX since December 2024, including 1 upgrade and 1 downgrade. Across 11 firms with a VRTX price target in the last 12 months, the median target is $575. Oppenheimer's $600 is 4% above that.
- Current rating
- Outperform
- Price target
- $600
- Median target, all firms
- $575
- Actions on VRTX
- 3
Oppenheimer price target on VRTX
Every Oppenheimer rating on VRTX
- Mar 10, 2026
- Feb 13, 2026
- Dec 19, 2024
How other firms rate VRTX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Outperform | $594 | Sep 21, 2026 |
| Morgan Stanley | Overweight | $665 | Sep 2, 2026 |
| Truist Securities | Buy | $542 | May 27, 2026 |
| Maxim Group | Buy | $575 | Mar 18, 2026 |
| Jefferies | Buy | $580 | Mar 10, 2026 |
| Oppenheimer | Outperform | $600 | Mar 10, 2026 |
| Barclays | Overweight | $606 | Jan 28, 2026 |
| RBC Capital Markets | Outperform | $546 | Jan 22, 2026 |
| Bernstein | Outperform | Jan 12, 2026 | |
| UBS | Buy | $535 | Jan 7, 2026 |
| Wolfe Research | Outperform | $548 | Jan 6, 2026 |
| Scotiabank | Sector Outperform | $495 | Nov 13, 2025 |
Questions about Oppenheimer and VRTX
- What is Oppenheimer's price target for VRTX?
- Oppenheimer's latest stated price target for Vertex Pharmaceuticals Incorporated (VRTX) is $600, from its action on Mar 10, 2026.
- What is Oppenheimer's rating on VRTX?
- Oppenheimer rates VRTX Outperform, a bullish rating, as of Mar 10, 2026.
- When did Oppenheimer last change its view on VRTX?
- On Mar 10, 2026, Oppenheimer raises its price target to $600 from $540, keeps Outperform.
- How does Oppenheimer's VRTX target compare with other analysts?
- Across 11 firms with a VRTX price target in the last 12 months, the median target is $575. Oppenheimer's $600 is 4% above that.
More VRTX rating histories
- Leerink Partners7
- Morgan Stanley6
- Maxim Group3
- Jefferies3
- RBC Capital Markets7
- Bernstein3
- Wolfe Research5
- Raymond James3
- Wells Fargo3
- Canaccord Genuity4
- Piper Sandler3
All Oppenheimer ratingsVRTX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.